IQVIA Holdings Inc. (IQV) is experiencing mixed performance with the stock demonstrating both strength and underperformance on various trading days. Multiple institutions, including Amalgamated Bank and Gulf International Bank UK, have reduced their stakes. Yet, others like Fiduciary Family Office and SFE Investment Counsel have increased their holdings. Though the company faces some market challenges, it saw strong EPS growth in Q3 2024, and both its earnings and revenues surpassed estimates. IQVIA's CFO, Ron Bruehlman, is set to present at the UBS Global Healthcare Conference, signifying the company's involvement in key industry events. Truist maintains a 'Buy' rating for IQV, although the stock target has been cut to $265, while JPMorgan Chase has lowered expectations for IQVIA's stock price. Despite this, IQVIA figures among UBS’s top tech-based disruptive stocks for 2030. IQVIA's reliance on international revenue is an aspect worth noting, as is the recent acquisition of shares by Impax Asset Management Group. Perhaps worrying are signals of bearishness observed through insider stock disposals. Overall, IQVIA seems to balance risks and rewards, making an intriguing prospect in the biotech sector.
Iqvia Holdings IQV News Analytics from Fri, 16 Feb 2024 08:00:00 GMT to Fri, 08 Nov 2024 21:58:00 GMT -
Rating 2
- Innovation 4
- Information 3
- Rumor -4
